A bifurcated proteoglycan binding small molecule carrier for siRNA delivery.
A wider application of siRNA- and miRNA- based therapeutics is restricted by the currently available delivery systems. We have designed a new type of small molecule carrier (SMoC) system for siRNA modeled to interact with cell surface proteoglycans. This bifurcated SMoC has similar affinity for the model proteoglycan heparin to an equivalent polyarginine peptide and exhibits significant mRNA knockdown of protein levels comparable to lipofectamine and the previously reported linear SMoC.
The Wolfson Institute for Biomedical Research, UCL, Gower Street, London, WC1E 6BT, UK.
Matt
M
Gooding
Derick
D
Adigbli
A W
AW
Edith Chan
Roberta J
RJ
Melander
Alexander J
AJ
MacRobert
David L
DL
Selwood
D002460:Cell Line; D004337:Drug Carriers / Q000737:chemistry* / Q000378:metabolism; D006493:Heparin / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000737:chemistry; D008958:Models, Molecular; D011509:Proteoglycans / Q000378:metabolism*; D034622:RNA Interference; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics; D014162:Transfection / Q000379:methods
D004337:Drug Carriers; D008055:Lipids; C086724:Lipofectamine; D011509:Proteoglycans; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C036090:heparin proteoglycan; D006493:Heparin
RNAi and antisense techniques; biophysical chemistry; carbohydrate; chemical biology; lipid; nucleic acid